CJC-1295 and ipamorelin both raise growth hormone (GH), but through different receptors and on different timescales. CJC-1295 is a GHRH analogue: it acts on the GHRH receptor, and the DAC version stays in circulation for days. Ipamorelin is a ghrelin-receptor agonist (a GH secretagogue) with a short, sharp GH pulse. They are not the same compound and they are not interchangeable. In Australia, both are also tightly regulated, which matters before any purchase or use. This guide compares them on mechanism, human data, safety and legal status.
TL;DR
- Different targets: CJC-1295 mimics GHRH. Ipamorelin activates the ghrelin receptor (GHSR-1a). Their GH effects differ in duration and shape.
- DAC matters: CJC-1295 with DAC has a half-life of roughly 6 to 8 days in humans. The version without DAC has no peer-reviewed human studies, according to a 2026 review.
- Evidence is narrow: Human data show hormone changes (GH, IGF-1) and short-term tolerability. They do not show muscle, fat loss or performance benefits in healthy people.
- Australian status: The TGA names CJC-1295 as an unapproved peptide example. Both peptides are prescription-only medicines, and WADA prohibits both in sport.
- Research supply: For laboratory work, identity and purity documentation (HPLC, mass spec, Certificate of Analysis) is the baseline requirement.
Table of Contents
- CJC-1295 vs ipamorelin at a glance
- How CJC-1295 works
- How ipamorelin works
- Mechanism compared: pulse versus sustained signal
- What the research shows, and what it does not
- GHRP-6 vs ipamorelin
- Safety signals reported
- Australian regulatory status
- Choosing between them for a research design
- What to verify on any peptide batch
- Our perspective
- Research catalogue and batch documentation
- FAQ
- Sources
CJC-1295 vs ipamorelin at a glance
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH analogue | GH secretagogue, ghrelin-receptor agonist |
| Receptor | GHRH receptor | GHSR-1a |
| Duration (human data) | DAC form: half-life about 5.8 to 8.1 days | GH peak about 40 to 60 minutes after dosing |
| GH pattern | Raises baseline (trough) GH; pulses persist | Clear, short GH pulse |
| Human evidence | Two Phase I-type trials of the DAC form, 2006 | Phase I studies; Phase 2 postoperative ileus work |
| Variants | With DAC, without DAC | Single compound |
| WADA status | Prohibited at all times | Prohibited at all times |
Sources for each row are given in the sections below.
How CJC-1295 works
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone. It binds the GHRH receptor on pituitary somatotrophs and prompts GH release. Whether the result is a brief signal or a prolonged one depends on the variant.
CJC-1295 with DAC
DAC stands for Drug Affinity Complex. The modification lets the peptide bind to serum albumin, which extends its life in the body. In two randomized, placebo-controlled, double-blind, ascending-dose trials in healthy adults aged 21 to 61, a single subcutaneous dose raised mean GH 2- to 10-fold for 6 days or more. Mean IGF-I rose 1.5- to 3-fold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days, and no serious adverse reactions were reported.
A separate 2006 study in healthy men aged 20 to 40 gave a single 60 or 90 μg/kg injection. It found basal (trough) GH up 7.5-fold, overall mean GH up 46% and IGF-I up 45%, while the frequency and magnitude of GH pulses were unaltered. In plain terms, the DAC form raised the floor of GH secretion without removing its pulsatile pattern.
CJC-1295 without DAC
The version without DAC is shorter-acting, because it lacks the albumin-binding modification. This is the variant most often discussed in combination with ipamorelin. Its evidence base is thin: a 2026 Frontiers in Endocrinology review lists CJC-1295 without DAC as having no peer-reviewed human studies. Any literature that cites DAC trial results for the non-DAC form is extrapolating.
When reading a product listing or a paper, confirm which form is meant. The two share a name but differ in structure, half-life and data.
How ipamorelin works
Ipamorelin is a pentapeptide that acts as a ghrelin-receptor agonist. It was described in 1998 as a selective GH secretagogue. In the Raun et al. study, ipamorelin released GH from rat pituitary cells with potency and efficacy similar to GHRP-6 (EC50 1.3 nmol/l vs 2.2 nmol/l). In conscious swine its ED50 was 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6.
In a phase I study in healthy adults, the Frontiers review reports ipamorelin was generally well tolerated, with peak GH about 40 to 60 minutes after administration and no significant effects on other pituitary or adrenal hormones. That selectivity is the reason ipamorelin is often compared with broader secretagogues such as GHRP-6.
For a laboratory primer on how ipamorelin is discussed in muscle-related models, see our ipamorelin muscle research overview.
Mechanism compared: pulse versus sustained signal
The two compounds act at different points on the GH axis.
- CJC-1295 (GHRH pathway): raises the capacity of the pituitary to release GH. The DAC form keeps that signal present for days.
- Ipamorelin (ghrelin pathway): triggers a release event with a peak within the first hour.
The Ionescu and Frohman finding is relevant here. Because GH pulses persisted after a DAC dose, the sustained GHRH signal did not abolish pulsatility. How the two mechanisms interact in a combined protocol is a design question, not a settled one. Published human trials of the pair together are not part of the evidence reviewed for this guide, so any statement about synergy should be read as a hypothesis.
What the research shows, and what it does not
CJC-1295 evidence
The human literature is small and short. The 2006 trials established hormone response, pharmacokinetics and short-term tolerability. An Australian professional source, Healthy Male, notes the work was designed to investigate hormone levels, drug behavior and short-term safety. It adds that there is no good-quality human evidence that either peptide builds muscle, reduces body fat, speeds recovery or improves performance in healthy people.
The Frontiers review adds that neither CJC-1295 variant is approved as a therapeutic by major regulators such as the FDA or EMA. It also reports the FDA placed CJC-1295 on Category 2 of its Bulk Drug Substances List, citing vasodilatory reactions and tachycardia reports.
Ipamorelin evidence
The same review describes Phase I human studies and clinical development in postoperative ileus, with no efficacy data for GH-related metabolic indications. Healthy Male stresses that a change on a blood test is not the same as a proven health benefit, and that much of the ipamorelin research cited comes from animal studies that cannot confirm the same effects in people.
Broader context
A 2025 Journal of Sexual Medicine abstract screened 277 studies on peptides in men's health, and 125 met criteria. It concludes that clinical efficacy and safety remain underreported, with a need for rigorous RCTs and long-term studies. That is the honest frame for any peptide in this class: mechanism is well characterized, clinical outcome data are not.
GHRP-6 vs ipamorelin
Readers often compare ipamorelin with GHRP-6. Both act on the ghrelin receptor (GHSR-1a), but their profiles differ.
| Feature | GHRP-6 | Ipamorelin |
|---|---|---|
| Receptor | GHSR-1a | GHSR-1a |
| GH release | Robust, pulsatile in controlled human studies | Clear GH response in phase I |
| Appetite | Consistent appetite-stimulating response | Not a reported feature in the reviewed phase I data |
| Cortisol, prolactin | Transient increases reported | No ACTH or cortisol release significantly different from GHRH stimulation, in swine, at doses over 200-fold above ED50 |
The comparison above follows the 2026 Frontiers review. The swine data come from the 1998 Raun study, so they are animal findings.
GHRP-6 studies
GHRP-6 has older human data. In a 1995 study, repeated intravenous boluses (4 × 50 micrograms) in healthy men raised GH, ACTH and cortisol, and increased stage 2 sleep. GH averaged 15.4 ng/ml against 5.5 ng/ml after placebo.
A 1999 follow-up found that route and dose changed the result. Intranasal GHRP-6 at 30 microg/kg raised night-time GH. Oral GHRP-6 at 300 microg/kg left GH, ACTH and cortisol unchanged. The Frontiers review adds that direct evidence of body-composition change in humans is limited, and that preclinical cardioprotective findings lack human confirmation.
Safety signals reported
In the CJC-1295 DAC trials, the most frequent adverse events were injection-site reactions: transient pain, swelling and induration, sometimes with local urticaria. No serious adverse reactions were reported, and the FDA presentation notes a cumulative effect after multiple doses.
Healthy Male lists injection-site reactions, headache, nausea and diarrhea in the short human study. It also notes that persistently high GH may affect fluid retention, blood glucose and insulin response, and that long-term data are lacking.
Product quality is a separate risk. The TGA's April 2026 advisory says unapproved peptide products have not been assessed for safety, quality or effectiveness. It states that manufacture, sterility and actual contents may be unknown, and that injected products can carry risks of contamination, infection or local tissue damage. Reported concerns include severe allergic reactions needing adrenaline and hospitalization, systemic inflammatory response syndrome, insomnia, blurred vision and tendon injuries.
Anyone who has had a reaction after using an unapproved peptide should see a GP or go to an emergency department. Our lab guides cover vial contamination warning signs and why sterility matters in peptide research.
Australian regulatory status
The legal position in Australia is specific and should be understood first.
- TGA: the April 2026 advisory names CJC-1295 among examples of unapproved peptide products not included in the ARTG. It does not distinguish forms of CJC-1295, and ipamorelin is not among its named examples. The TGA says it is monitoring import, supply, compounding and advertising from both safety and enforcement angles.
- Poisons Standard: news.com.au reports that popular online products including CJC-1295 and ipamorelin are prescription-only medicines listed in Appendix D, and that possessing them without a valid prescription is an offense.
- Sport: section S2.2.4 of the WADA 2026 Prohibited List, effective 1 January 2026, prohibits GHRH analogues including CJC-1295, and secretagogues including ipamorelin, at all times. GHRP-1 through GHRP-6 are also listed.
Research-grade material is supplied for laboratory use by qualified researchers, not as a product for human use. For the detail, read our guides on TGA peptide rules in Australia and peptide prescription requirements. Anyone considering human use should speak to a doctor about lawful, prescribed options.
Choosing between them for a research design
For laboratory work, selection follows the question being asked.
- Sustained GHRH-axis stimulation: the DAC form of CJC-1295 has the published pharmacokinetic and pharmacodynamic data.
- Short GH pulse via the ghrelin receptor: ipamorelin, with GH peaking within the first hour in phase I work.
- Broader ghrelin-pathway effects, including appetite and cortisol: GHRP-6 has the older human literature.
- Combined designs: define the CJC-1295 variant, dose, timing and endpoints in advance. Report DAC status explicitly, because results from one form do not transfer to the other.
For wider context, see peptide types and uses explained for researchers.
What to verify on any peptide batch
Identity and purity decide whether results are interpretable. A research buyer should check:
- Purity by HPLC: our catalogue peptides are each verified to ≥99% by HPLC.
- Identity by mass spectrometry: molecular weight should match the stated compound and variant.
- Certificate of Analysis: batch-specific and traceable to the vial received. COAs are available on request from us.
- Sterility documentation: see what COAs can prove about sterility and what a 14-day USP <71> test shows.
- Handling: reconstitution solvents and PPE are covered in peptide solvent safety.
- Grade: RUO versus GMP peptides differ in cost and intended use.
Our perspective
We supply research-grade peptides to qualified researchers and institutions. For a pair like CJC-1295 and ipamorelin, the published literature is clear on mechanism and limited on outcomes. That makes compound identity the first variable in any study.
Each batch we supply is independently tested by HPLC and mass spectrometry, with traceable batch documentation and a Certificate of Analysis on request. Our catalogue holds over 22 compounds across metabolic, cognitive, tissue repair, longevity, immunology and cosmetic research. Our position: a protocol is only as reproducible as the material in the vial.
We also operate in Australia. Our materials are for laboratory research, and we direct readers to the TGA and a doctor for any question about human use.
Tintastic
Research catalogue and batch documentation
Peptastic Labs lists research peptides in lines including Metabolic, Cognitive & Neuro, Tissue & Repair, Longevity, Cosmetic Science, Blends, Hormone & Reproductive, and Ancillaries & Reagents. Bulk and wholesale options are available. Orders can be placed online, including via Telegram or WhatsApp pre-filled checkout.
Browse the full research peptide catalogue and request the Certificate of Analysis for the batch you need.
FAQ
Are CJC-1295 and ipamorelin the same thing?
No. CJC-1295 is a GHRH analogue acting on the GHRH receptor. Ipamorelin is a GH secretagogue acting on the ghrelin receptor. Both raise GH, but their duration, receptor and evidence base differ.
What is the difference between CJC-1295 with DAC and without DAC?
DAC extends the peptide's life in the body. The DAC form showed a half-life of roughly 5.8 to 8.1 days in 2006 human trials. The version without DAC is shorter-acting and, per a 2026 review, has no peer-reviewed human studies.
Do studies show CJC-1295 or ipamorelin build muscle or burn fat?
Not in healthy people. Human CJC-1295 studies measured GH, IGF-1, pharmacokinetics and short-term safety. Healthy Male states there is no good-quality human evidence for muscle gain, fat loss, recovery or performance benefits.
Are CJC-1295 and ipamorelin legal in Australia?
The TGA lists CJC-1295 as an unapproved peptide example, and news.com.au reports both are prescription-only in Appendix D of the Poisons Standard. Possession without a valid prescription is an offense. Both are also banned in sport by WADA.
How does GHRP-6 compare with ipamorelin?
Both act on the ghrelin receptor. GHRP-6 has a broader profile, with a consistent appetite response and transient cortisol and prolactin rises in human studies. Ipamorelin did not raise ACTH or cortisol significantly in swine data.
Sources
- Teichman et al. 2006, Prolonged stimulation of GH and IGF-I by CJC-1295
- Ionescu and Frohman 2006, Pulsatile GH secretion persists during CJC-1295
- Frontiers in Endocrinology 2026, The emerging landscape of performance-enhancing peptides
- Healthy Male, CJC-1295 and ipamorelin: evidence, risks and legality
- Journal of Sexual Medicine 2025, Peptides in practice
- Raun et al. 1998, Ipamorelin, the first selective GH secretagogue
- Frieboes et al. 1995, GHRP-6 stimulates sleep, growth hormone, ACTH and cortisol
- Frieboes et al. 1999, Effects of GHRP-6 on the nocturnal secretion of GH, ACTH and cortisol
- FDA presentation, Selected peptides and small molecules
- TGA, Understanding your responsibilities when importing, compounding and supplying unapproved peptide products
- news.com.au, Kids as young as 12 secretly injecting peptides
- WADA 2026 Prohibited List